New Delhi, Jun 6 (PTI) An expert committee under the Central Drug Regulatory Authority has recommended continuation of phase-II clinical trial of the Serum Institute of India (SII)'s vaccine against dengue after noting the promising results of the phase-I interim clinical trial.

The Serum Institute conducted the phase-I, double-blind, randomised, placebo-controlled trial on 60 healthy individuals aged 18 to 45 years in Australia to assess safety and immunogenicity of the tetravalent live attenuated dengue vaccine.

Also Read | What Is the Oath of the Prime Minister of India? Who Administers the Oath of Office and Secrecy to PM?.

A tetravalent live attenuated dengue vaccine was manufactured in India after receipt of vaccine strains from NIAID, NIH, USA.

"A single dose of dengue vaccine was safe and well tolerated in adults. The vaccine was highly immunogenic with trivalent or tetravalent seroconversion and seropositivity in most of the participants," stated the study results published in Vaccine, a journal by Elsevier, last year in August.

Also Read | ICAI CA Foundation Exam 2024: Admit Card for CA Foundation June Examination Released at eservices.icai.org, Know Steps To Download Hall Ticket.

In light of recommendation of the subject expert committee dated July 18, 2023, the SII presented phase-I interim clinical trial report of Dengue Tetravalent Vaccine (Live, Attenuated) which was discussed by the panel on May 31.

"After detailed deliberation, the committee noted the results of Phase I interim clinical trial and recommended for continuation of Phase II clinical trial as per approved protocol," the SEC recommendations stated.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)